News

ANZUPGO® (delgocitinib) Cream Is Now the First and Only FDA-Approved Treatment for Moderate-to-Severe Chronic Hand Eczema (CHE) in Adults
LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...
Healio2d
FDA approves Anzupgo for chronic hand eczema
The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...
Managed Healthcare Executive2d
Anzupgo FDA Approved as First Treatment Meant for Chronic Hand Eczema in Adults
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
The Pharma Letter3d
FDA green light for LEO’s Anzupgo
Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has ...
Pharmabiz1d
US FDA approves LEO Pharma’s Anzupgo cream for the treatment of moderate-to-severe chronic hand eczema
Ballerup, Denmark Saturday, July 26, 2025, 15:00 Hrs [IST] ...
Fierce Pharma3d
Leo roars to key FDA nod for Anzupgo to treat chronic hand eczema
Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...
PMLive3d
LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema
LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...
WebMD3d
FDA OKs New Steroid-Free Skin Cream for Hand Eczema
The FDA has approved a new treatment, sold under the name Anzupgo and containing a drug called delgocitinib, as the first skin cream for adults with long-term or chronic hand eczema (CHE), which ...
BioWorld3d
US FDA approves first hand eczema treatment: Leo Pharma’s Anzupgo
Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received ...
Pharmabiz10mon
LEO Pharma’s Anzupgo cream receives European marketing approval for ...
Anzupgo is a topical pan-JAK inhibitor for the treatment of moderate to severe CHE. It inhibits the activation of JAK-STAT signalling, which plays a key role in the pathogenesis of CHE. Currently, ...
Business Wire1y
LEO Pharma Receives Positive CHMP Opinion of Anzupgo
About Anzupgo ® (delgocitinib cream) Anzupgo ® (delgocitinib cream) is an investigational topical pan-Janus kinase (JAK) inhibitor for moderate to severe CHE.